JPRN-UMIN000005345已完成1 期
Phase 1 & 2 clinical trial using peptide vaccine for VEGFR1 & 2 in combination with S-1 and Cisplatin for patients with advanced gastric cancer (HLA-A*0201) - Clinical trial of VEGFR vaccine with S-1 and Cisplatin (0201)
Osaka University, Graduate School of Medicine, Department of Gastroenterological Surgery0 个研究点目标入组 15 人开始时间: 2011年3月31日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 74years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The exclusion criteria were as follows 1)patients with serious concomitant disease 2)pregnancy 3)lactating 4)hope pregnancy 5)uncontrolled infection 6)cannot stopped steroids or immunosuppressing drug 7)simultaneous or metachronous double cancers 8)unhealed external injury 9)patients with ileus and interstitial lung disease 10)the cases whom the doctors define as inappropriate
研究者
相似试验
已完成
1 期
Phase 1 & 2 clinical trial using peptide vaccine for VEGFR1 & 2 in combination with S-1 and Cisplatin for patients with advanced gastric cancerunresectable or recurrent gastric cancerJPRN-UMIN000005007Osaka University, Graduate School of Medicine, Department of Gastroenterological Surgery30
已完成
不适用
Phase II clinical trial of WT1 peptide-based vaccine combined with Temozoromide for patients with glioblastoma.GlioblastomaJPRN-UMIN000026965Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine35
尚未招募
1 期
Phase II clinical trial of WT1 peptide-based vaccine for pediatric patients with recurrent malignant gliomaMalignant Glioma DIPGJPRN-UMIN000013258Osaka university graduate school of medicine18
已完成
1 期
Phase I/II clinical trial of WT1 peptide-based vaccine for the patients with malignant tumors.Malignant solid tumors, Malignant lymphoma, Multiple Myeloma, Acute leukemiaJPRN-UMIN000002001Department of Cancer immunotherapy, Osaka University Graduate School of Medicine30
已完成
1 期
Phase I Clinical trial of personalized peptide vaccine in combination with humanized anti-IL6 receptor monoclonal antibody for refractory colorectal cancer patientscolorectal cancer patients refractory to conventional treatmentsJPRN-UMIN000007493Kurume University Cancer Vaccine Center18